FDA calls partial halt to Phase I trial of Curis cancer drug

The FDA has placed a partial clinical hold on the Phase I trial of Curis' (CRIS) CUDC-427 treatment for advanced and refractory solid tumors or lymphomas.

The FDA ordered the halt following the death a patient who suffered liver failure a month after discontinuing treatment with CUDC-427.

Curis won't be able to enroll new patients for the study until it has met various FDA requirements; all the subjects in the trial have stopped taking the drug due to disease progression, or patient or physician discretion

The company licensed CUDC-427 from Roche's (RHHBY) Genentech.

Curis' shares sink 10.5%.

Curis' Q3 results. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs